CompletedPhase 2NCT02921269
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Claire F FriedmanJHU Sidney Kimmel Comprehensive Cancer Center LAO
- Intervention
- Atezolizumab(drug)
- Enrollment
- 11 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2017 – 2021
Study locations (22)
- Los Angeles County-USC Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Keck Medical Center of USC Pasadena, Pasadena, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Emory University Hospital Midtown, Atlanta, Georgia, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02921269 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital